MicroRNA‑525 enhances chondrosarcoma malignancy by targeting F‑spondin 1

Liu, Bo; Song, Xiandong; Yan, Zhaowei; Yang, Hao; Shi, Yingchao; Wu, Jintao

doi:10.3892/ol.2018.9711

Cited by 5 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-525-5p is differentially expressed in many human cancer types, including CRC. [38][39][40] To assess the regulatory roles of miR-525-5p in CRC, we conducted a series of functional assays. Ectopic miR-525-5p expression led to a significant reduction in cellular proliferation, migration, and invasion as well as in an increase in apoptosis in CRC cells.…”

Section: Discussionmentioning

confidence: 99%

<p>Long Noncoding RNA VPS9D1-AS1 Sequesters microRNA-525-5p to Promote the Oncogenicity of Colorectal Cancer Cells by Upregulating HMGA1</p>

Liu

Zhang

Jin

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: The long noncoding RNA VPS9D1 antisense RNA 1 (VPS9D1-AS1) has emerged as a critical regulator in non-small-cell lung, gastric, and prostate cancers. In this study, we measured the expression levels of VPS9D1-AS1 in colorectal cancer (CRC) and determined the role of VPS9D1-AS1 in regulating the biological activities of CRC cells. In addition, we thoroughly elucidated the molecular mechanism mediating the oncogenic activities of VPS9D1-AS1 in CRC. Methods: The expression levels of VPS9D1-AS1 in CRC tissues and cell lines were detected via quantitative reverse transcription-polymerase chain reaction. Loss-of-function experiments were performed to detect the effects of VPS9D1-AS1 silencing on CRC cell proliferation, apoptosis, migration, and invasion as well as on tumor growth in vivo. Bioinformatics analysis predicted the potential microRNAs (miRNAs) interacting with VPS9D1-AS1, and this prediction was further confirmed via RNA immunoprecipitation and luciferase reporter assays. Results: Our results demonstrated the upregulated expression of VPS9D1-AS1 in CRC tissues and cell lines. Functionally, VPS9D1-AS1 interference suppressed CRC cell proliferation, migration, and invasion and promoted cell apoptosis in vitro. In addition, the loss of VPS9D1-AS1 hindered tumor growth in vivo. Mechanistic studies identified VPS9D1-AS1 as a competing endogenous RNA in CRC cells, in which VPS9D1-AS1 acted as a molecular sponge of miR-525-5p and consequently increased the expression of high-mobility group AThook 1 (HMGA1). Moreover, rescue experiments revealed that the regulatory effects of VPS9D1-AS1 deficiency on CRC cells were abolished after miR-525-5p inhibition or HMGA1 restoration. Conclusion: The newly identified competing endogenous RNA pathway involving VPS9D1-AS1, miR-525-5p, and HMGA1 is implicated in the control of CRC progression and may provide an effective target for CRC diagnosis and therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Long Noncoding RNA VPS9D1-AS1 Sequesters microRNA-525-5p to Promote the Oncogenicity of Colorectal Cancer Cells by Upregulating HMGA1</p>

Liu

Zhang

Jin

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…However, a compelling clue lies in the significantly lower levels of miR-525, a microRNA directly targeting SPON1, observed in chondrosarcoma patients. This suggests a potential regulatory pathway: decreased miR-525 expression could contribute to increased malignancy by deregulating SPON1, leading to enhanced cell migration and invasion [ 45 ]. This indicates miR-525′s potential as a biomarker for the progression of chondrosarcoma.…”

Section: Diagnostics and Biomarkers Of Progressionmentioning

confidence: 99%

MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma

Skipar,

Dey,

Piątkowski

et al. 2024

IJMS

View full text Add to dashboard Cite

Chondrosarcoma, the second most common primary malignant bone tumor, originates from cartilaginous tissue and accounts for almost 20% of all primary bone tumors. The management of chondrosarcoma remains challenging due to its diverse clinical course and prognosis, which can range from benign to highly aggressive with a huge risk of metastasis. Emerging research has demonstrated the importance of microRNA (miRNA) dysregulation in the pathogenesis of chondrosarcoma. MiRNAs are small, noncoding RNA molecules that play an essential role in gene expression regulation by targeting specific messenger RNAs (mRNAs) for degradation or translational repression. This article provides an extensive review of current miRNA research in chondrosarcoma, focusing on diagnostic strategies, cell cycle regulation, drug resistance, biomarkers of progression, and stem cell phenotype. We will examine recent studies identifying differentially expressed miRNAs in chondrosarcoma compared to normal cartilage tissue, exploring their potential as diagnostic and prognostic biomarkers. Furthermore, we will discuss the role of miRNAs in regulating cell cycle progression and their potential as therapeutic targets to overcome drug resistance. We will also investigate the prospective utility of miRNAs as biomarkers of progression and their role in modulating the stem cell phenotype of chondrosarcoma cells. This article offers a comprehensive analysis of current miRNA research in chondrosarcoma, focusing on its potential as diagnostic and prognostic biomarkers, therapeutic targets, and regulators of disease progression. By integrating the latest discoveries in this field, we aim to contribute to the development of novel approaches to the prevention, diagnosis, and treatment of chondrosarcoma, ultimately enhancing patient outcomes.

show abstract

“…MicroRNA-525 can also inhibit tumor cell proliferation, migration and invasion. Overexpression of miR-525 can inhibit the migration and invasion of chondrosarcoma cells and induce cell apoptosis, and downregulated miR-525 activates the FAK/Src/PI3K/Akt signaling pathway by targeting F-spondin1 gene to promote the malignant progression of chondrosarcoma [15].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic role of microRNA-525 in different cancers: A systematic review and meta-analysis

ZHAO,

PAN,

GAO

et al. 2024

Preprint

View full text Add to dashboard Cite

Background New prospect of cancer therapeutical management seems to be early diagnosis and prognosis prediction by microRNAs. The aim of our study is to explore the role of miR-525 in cancer diagnosis and prognosis through a systematic review and meta-analysis. Methods We conducted systematic search through PubMed, Embase, Web of Science, Scopus, Medline, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases up to November 25, 2023, regardless of language restrictions. Sensitivity, specificity, and diagnostic odds ratio (DOR) were extracted for diagnostic meta-analysis, while hazard ratio (HR) with 95% confidence interval (CI) for prognostic meta-analysis. Subgroup analysis and publication bias analysis were performed appropriately to investigate possible sources of heterogeneity. Results A total of 8 studies were included in the meta-analysis, of which 7 were used for diagnostic meta-analysis, covering 559 patients, and 3 were used for prognostic meta-analysis, covering 324 patients. The pooled sensitivity was 0.75 (95%CI = 0.70 to 0.79), specificity was 0.73 (95%CI = 0.68 to 0.78), DOR was 13.08 (95%CI = 4.18 ~ 40.91), and the area under the curve ratio (AUC) was 0.86 (95%CI = 0.83–0.89). Subgroup analysis showed that miR-525 may have good diagnostic ability in the early TNM stage of cancer. Prognostic meta-analysis showed that low miR-525 expression in patients was associated with preferable survival (HR = 0.17, 95%CI = 0.07–0.9). Conclusions Our findings suggest that miR-525 could be used as a potential biomarker for cancer patients. Low expression of miR-525 in cancers predicted a good prognosis.

show abstract

MicroRNA‑525 enhances chondrosarcoma malignancy by targeting F‑spondin 1

Cited by 5 publications

References 35 publications

<p>Long Noncoding RNA VPS9D1-AS1 Sequesters microRNA-525-5p to Promote the Oncogenicity of Colorectal Cancer Cells by Upregulating HMGA1</p>

<p>Long Noncoding RNA VPS9D1-AS1 Sequesters microRNA-525-5p to Promote the Oncogenicity of Colorectal Cancer Cells by Upregulating HMGA1</p>

MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma

Diagnostic and prognostic role of microRNA-525 in different cancers: A systematic review and meta-analysis

Contact Info

Product

Resources

About